NASDAQ:FMI - Foundation Medicine Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $137.00 0.00 (0.00 %) (As of 11/21/2018 09:38 AM ET)Previous Close$137.00Today's Range$137.00 - $137.0052-Week Range$31.70 - $137.20VolumeN/AAverage Volume621,352 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Foundation Medicine, Inc. provides various molecular information products in the United States. The company's molecular information platform includes proprietary methods and algorithms to analyze specimens across various types of cancer, as well as for incorporating that information into clinical care; and offers genomic insights about each patient's individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted therapies and immunotherapies. It provides clinical products, such as FoundationOne for solid tumors; FoundationOne Heme for blood-based cancers, or hematologic malignancies, including leukemia, lymphoma, and sarcomas; Foundation Assay for Circulating Tumor; FoundationFocus CDxBRCA, a diagnostic assay to aid in identifying women with ovarian cancer; and FoundationOne CDx, a diagnostic assay for solid tumors. The company also offers FoundationCORE, a knowledgebase to publish scientific and medical advances, and foster relationships throughout the oncology community. In addition, it has strategic collaboration agreements with F. Hoffmann-La Roche Ltd.; and Genentech, Inc. Foundation Medicine, Inc. has a collaboration with The European Organisation for Research and Treatment of Cancer to advance precision medicine using comprehensive genomic profiling to facilitate clinical trial enrollment. It also has a three-party collaboration agreement with F. Hoffmann-La Roche Ltd and DIAN Diagnostics Group, Co., Ltd. to integrate the company's comprehensive genomic profiling assays into clinical patient care in mainland China. The company was founded in 2009 and is headquartered in Cambridge, Massachusetts. Foundation Medicine, Inc. is a subsidiary of Roche Holdings, Inc. Receive FMI News and Ratings via Email Sign-up to receive the latest news and ratings for FMI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FMI Previous Symbol CUSIPN/A Webwww.foundationmedicine.com Phone617-418-2200 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees662 Outstanding SharesN/AMarket Cap$0.00 OptionableOptionable Foundation Medicine (NASDAQ:FMI) Frequently Asked Questions What is Foundation Medicine's stock symbol? Foundation Medicine trades on the NASDAQ under the ticker symbol "FMI." How were Foundation Medicine's earnings last quarter? Foundation Medicine Inc (NASDAQ:FMI) released its quarterly earnings data on Wednesday, May, 2nd. The company reported ($1.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.10) by $0.08. The company earned $52.84 million during the quarter, compared to analyst estimates of $44.99 million. The business's revenue was up 100.7% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.31) EPS. View Foundation Medicine's Earnings History. What price target have analysts set for FMI? 4 equities research analysts have issued 12 month target prices for Foundation Medicine's stock. Their forecasts range from $73.00 to $90.00. On average, they anticipate Foundation Medicine's stock price to reach $81.00 in the next twelve months. This suggests that the stock has a possible downside of 40.9%. View Analyst Price Targets for Foundation Medicine. What is the consensus analysts' recommendation for Foundation Medicine? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Foundation Medicine in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Foundation Medicine. Has Foundation Medicine been receiving favorable news coverage? News articles about FMI stock have trended positive on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Foundation Medicine earned a media sentiment score of 2.1 on InfoTrie's scale. They also gave news articles about the company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an impact on the stock's share price in the near term. Who are some of Foundation Medicine's key competitors? Some companies that are related to Foundation Medicine include Aeon Global Health (AGHC), CBA Florida (CBAI), ELEKTA AB/ADR (EKTAY), First Choice Healthcare Solutions (FCHS) and PotNetwork (POTN). Who are Foundation Medicine's key executives? Foundation Medicine's management team includes the folowing people: Mr. Troy Cox, CEO, Pres & Director (Age 54)Mr. Michael Doherty, Head of Product Devel. (Age 59)Mr. Jason Ryan, Chief Financial Officer (Age 44)Mr. Konstantin Fiedler, Chief Operating Officer (Age 52)Mr. Tom Godden, Chief Information Officer How do I buy shares of Foundation Medicine? Shares of FMI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Foundation Medicine's stock price today? One share of FMI stock can currently be purchased for approximately $137.00. What is Foundation Medicine's official website? The official website for Foundation Medicine is http://www.foundationmedicine.com. How can I contact Foundation Medicine? Foundation Medicine's mailing address is 150 Second Street, Cambridge MA, 02141. The company can be reached via phone at 617-418-2200 or via email at [email protected] MarketBeat Community Rating for Foundation Medicine (NASDAQ FMI)Community Ranking: 1.7 out of 5 ()Outperform Votes: 176 (Vote Outperform)Underperform Votes: 340 (Vote Underperform)Total Votes: 516MarketBeat's community ratings are surveys of what our community members think about Foundation Medicine and other stocks. Vote "Outperform" if you believe FMI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FMI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/21/2018 by MarketBeat.com StaffFeatured Article: What are the benefits of a balanced fund?